William Blair Investment Management LLC Increases Stake in Twist Bioscience Corporation $TWST

Key Points

• William Blair Investment Management LLC increased its stake in Twist Bioscience Corporation by 2.6%, now owning approximately 6.52% of the company, valued at around $143.7 million.
• Twist Bioscience's stock has seen a decline, trading down 8.4%, and currently has a market capitalization of $1.70 billion.
• Analysts have mixed opinions on the stock, with a consensus rating of "Moderate Buy" and target price averaging $48.56, while others such as Evercore ISI have reduced their price objectives.

William Blair Investment Management LLC raised its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 2.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,906,604 shares of the company's stock after buying an additional 99,737 shares during the quarter. William Blair Investment Management LLC owned about 6.52% of Twist Bioscience worth $143,724,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of TWST. GAMMA Investing LLC boosted its position in Twist Bioscience by 68.1% during the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after acquiring an additional 303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock worth $85,000 after purchasing an additional 302 shares in the last quarter. Bayforest Capital Ltd boosted its holdings in shares of Twist Bioscience by 49.3% during the 1st quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock worth $191,000 after purchasing an additional 1,604 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its holdings in shares of Twist Bioscience by 8.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company's stock worth $222,000 after purchasing an additional 469 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new stake in shares of Twist Bioscience in the first quarter valued at approximately $228,000.

Twist Bioscience Trading Down 8.4%

NASDAQ TWST opened at $28.16 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The stock has a market capitalization of $1.70 billion, a P/E ratio of -19.42 and a beta of 2.38. The firm's 50-day moving average is $27.98 and its two-hundred day moving average is $32.31. Twist Bioscience Corporation has a 12 month low of $24.07 and a 12 month high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TWST shares. Evercore ISI lowered their price objective on Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 7th. Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research report on Wednesday, October 8th. Barclays cut their price objective on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a research report on Thursday, October 2nd. Finally, Cowen reiterated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus target price of $48.56.

Insider Buying and Selling

In other Twist Bioscience news, CAO Robert F. Werner sold 2,041 shares of the company's stock in a transaction on Monday, October 6th. The stock was sold at an average price of $32.19, for a total transaction of $65,699.79. Following the transaction, the chief accounting officer directly owned 46,413 shares in the company, valued at $1,494,034.47. This represents a 4.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dennis Cho sold 3,876 shares of Twist Bioscience stock in a transaction on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $124,768.44. Following the completion of the sale, the insider directly owned 98,710 shares of the company's stock, valued at $3,177,474.90. The trade was a 3.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,368 shares of company stock valued at $2,036,204 over the last quarter. 3.01% of the stock is owned by corporate insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.